CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen

Core Insights - CytoSorbents Corporation will have a significant scientific presence at the upcoming EACTS Annual Meeting, showcasing its advancements in blood purification technologies for cardiac surgery [1][2][3] Company Overview - CytoSorbents Corporation specializes in treating life-threatening conditions in intensive care and cardiac surgery through blood purification technologies [10] - The company’s lead product, CytoSorb®, is CE-mark approved in the EU and distributed in over 70 countries, with nearly 300,000 devices used to date [11] - CytoSorbents is also developing the DrugSorb™-ATR system for antithrombotic drug removal, which has received two FDA Breakthrough Device Designations [12] Upcoming Events - The EACTS Annual Meeting will take place from October 8–11, 2025, in Copenhagen, Denmark, expected to attract over 5,000 attendees [1] - CytoSorbents will present two high-profile scientific presentations and host a lunch symposium discussing the role of hemoperfusion technologies in cardiac surgery [2][4] Scientific Presentations - Presentations will include data on the intraoperative removal of direct oral anticoagulants in urgent cardiothoracic surgery and the impact of dual antiplatelet therapy on perioperative bleeding [4][6] - The first randomized controlled trial data will demonstrate the effectiveness of DrugSorb™-ATR in reducing levels of direct oral anticoagulants during urgent cardiac surgery [6] Symposium Topics - The lunch symposium will cover topics such as improving outcomes for endocarditis patients and the combination of VA ECMO with hemoadsorption in cardiogenic shock patients [5][7]